Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Want to see TRDA full AI Analyst Report?
TRDA Stock Chart & Stats
$13.99
-$0.56(-3.25%)
At close: 4:00 PM EST
$13.99
-$0.56(-3.25%)
Day’s Range― - ―
52-Week Range$4.93 - $16.45
Previous CloseN/A
Volume35.15K
Average Volume (3M)560.41K
Market Cap
$250.78M
Enterprise Value$225.64M
Total Cash (Recent Filing)$254.86M
Total Debt (Recent Filing)$49.75M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 12, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding38,820,618
10 Day Avg. Volume246,693
30 Day Avg. Volume560,413
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue39.32
Enterprise Value/Gross Profit-6.58
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
$18.75Price Target Upside34.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.96
Revenue Forecast (FY)$19.51M
Bulls Say, Bears Say
Bulls Say
Clinical Validation Of Delivery PlatformPositive Phase 1/2 topline results for ENTR-601-44 provide durable validation of Entrada’s intracellular delivery platform. Statistically significant functional improvement with clean safety reduces clinical risk across EEV-based programs, strengthening the platform's credibility for partnerships and broader pipeline advancement.
Diversified Clinical-stage Pipeline & PartnershipsA multi-program franchise across Duchenne, DM1 and inherited retinal diseases spreads program-specific binary risk. The Vertex-partnered program and multiple upcoming 2026 readouts create several durable value inflection opportunities and signal external validation that supports long-term strategic optionality.
Near-term Cash Runway And Modest LeverageA reported cash balance funding operations into Q3 2027 gives management time to advance key clinical programs and deliver readouts before needing material financing. Combined with modest debt and substantive equity on the balance sheet, this underpins near-to-medium term operational resilience while programs progress.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly -$132M TTM indicates heavy cash consumption to fund clinical development. If burn rates persist or timelines extend, the company will need external financing, raising dilution risk and potentially forcing funding-driven strategic compromises over the medium term.
Revenue Collapse And Earnings VolatilityA ~77% revenue decline and a swing to large net losses show reliance on sporadic collaboration revenue and high R&D spend. This earnings volatility limits predictability of internal funding, heightens dependence on successful clinical outcomes for future revenue, and weakens operating leverage sustainably.
Expanded Equity Plans Increase Dilution RiskApproval to expand equity compensation plans raises the potential for share count growth used to attract talent and align incentives. Given current cash burn and funding needs, broader equity issuance creates a lasting dilution channel that can pressure per-share returns for existing investors absent commensurate clinical or commercial progress.
Entrada Therapeutics Inc News
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $250.78M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -1.05.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 38,820,618 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.75 (34.02% Upside)
$18.75 (34.02% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.37%
12-Months-Change
Fundamentals
Return on Equity
-51.22%
Trailing 12-Months
Asset Growth
-31.03%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
TRDA Stock 12 Month Forecast
Average Price Target
$18.75
▲(34.02% Upside)
Technical Analysis
―
Black Diamond Therapeutics
―
C4 Therapeutics
―
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
35.99% Insiders
8.09% Mutual Funds
36.84% Other Institutional Investors
10.73% Public Companies and
Individual Investors